What is the 13F Pro Quality Score for TYRA?

13F Pro ranks Tyra Biosciences, Inc. (TYRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TYRA's current score at https://13fpro.ai/research/TYRA (free sign-up required for the full ranking).

Which hedge funds own the most TYRA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TYRA include RA CAPITAL MANAGEMENT, L.P., FMR, Nextech Invest, Ltd.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TYRA as soon as new 13F filings post.

Where does 13F Pro source TYRA data?

All Tyra Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tyra Biosciences, Inc. files with the SEC under CIK 1863127. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TYRA in?

Tyra Biosciences, Inc. (TYRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TYRA research updated on 13F Pro?

TYRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tyra Biosciences, Inc.(TYRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1863127 TYRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TYRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tyra Biosciences, Inc. (TYRA), a Healthcare sector company. TYRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Tyra Biosciences, Inc. reports net income of $-39.3M, free cash flow of $-32.7M. Top institutional holders of TYRA by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, Nextech Invest, Ltd., based on the most recent SEC filings. TYRA trades on the Nasdaq exchange and files with the SEC under CIK 1863127. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TYRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tyra Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-39.3M

Free Cash Flow

Q1 2026

$-32.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-38.7% YoY

$-119.9MFY 2025

FY22 $-55.3MFY23 $-69.1MFY24 $-86.5MFY25 $-119.9M

Operating Income

-27.4% YoY

$-132.8MFY 2025

FY22 $-58.9MFY23 $-79.9MFY24 $-104.2MFY25 $-132.8M

EPS (Diluted)

-33.1% YoY

$-2.01FY 2025

FY22 $-1.32FY23 $-1.62FY24 $-1.51FY25 $-2.01

Total Assets

-22.3% YoY

$282.6MFY 2025

FY22 $266.2MFY23 $225.9MFY24 $363.6MFY25 $282.6M

Op. Cash Flow

-36.4% YoY

$-95.1MFY 2025

FY22 $-50.3MFY23 $-50.1MFY24 $-69.8MFY25 $-95.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	$-119.9M -38.7%	$-86.5M -25.1%	$-69.1M -25.0%	$-55.3M
Operating Income	$-132.8M -27.4%	$-104.2M -30.3%	$-79.9M -35.7%	$-58.9M
EPS (Diluted)	$-2.01 -33.1%	$-1.51 +6.8%	$-1.62 -22.7%	$-1.32
Total Assets	$282.6M -22.3%	$363.6M +61.0%	$225.9M -15.1%	$266.2M
Operating Cash Flow	$-95.1M -36.4%	$-69.8M -39.2%	$-50.1M +0.3%	$-50.3M

AI Insight: TYRA Financial Trends

Tyra's operating losses accelerated sharply in Q1 2026 to $42M, while equity surged $129M—likely from financing—masking persistent cash burn.

• Operating losses widened from $24M in Q2 2024 to $42M in Q1 2026, a 75% deterioration over 18 months.

• Operating cash burn deepened to $33M in Q1 2026 from $10M in Q2 2024, indicating accelerating cash consumption.

• Equity jumped $129M quarter-over-quarter (Q4 2025: $259M → Q1 2026: $388M), suggesting capital raise to fund operations.

⚠ Net losses now $39M in Q1 2026 vs. $19M in Q2 2024; trajectory unsustainable without revenue inflection or further financing.

⚠ Revenue remains absent from all reported periods; clinical-stage company with no commercial product yet generating losses.

AI Insight: TYRA Ratio Trends

TYRA's returns metrics deteriorated sharply through 2025, with Q4 2025 ROIC hitting -56.4%, though Q1 2026 shows modest recovery.

• ROIC collapsed from -25.0% in Q2 2024 to -56.4% in Q4 2025, worsening each quarter before slight rebound to -43.3% in Q1 2026.

• ROE and ROA tracked ROIC downward, with Q4 2025 ROE at -52.2% and ROA at -47.9%, indicating persistent cash burn and negative earnings.

• Q1 2026 shows improvement across all metrics: ROE -40.6%, ROA -38.2%, ROIC -43.3%, all above Q4 2025 lows.

⚠ Sustained negative returns across all periods signal ongoing losses. Recovery in Q1 2026 must be validated in subsequent quarters to confirm inflection.

⚠ Operating margin, NPM, and leverage ratios unavailable; cash runway and burn rate critical unknowns for pre-revenue biotech.

Get alerted when TYRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tyra Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TYRA

RA CAPITAL MANAGEMENT, L.P.
$467.2M12,198,625 sh
FMR LLC
$296.7M7,747,648 sh
Nextech Invest, Ltd.
$155.3M4,055,861 sh
JANUS HENDERSON GROUP PLC
$148.9M3,890,589 sh
Alta Partners Management Company, L.P.
$146.4M3,823,425 sh
FARALLON CAPITAL MANAGEMENT LLC
$137.1M3,580,818 sh
TCG Crossover Management, LLC
$124.4M3,248,980 sh
Commodore Capital LP
$94.8M2,475,000 sh
BlackRock, Inc.
$84.9M2,217,929 sh
Paradigm Biocapital Advisors LP
$78.7M2,054,991 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$467.2M	12,198,625
FMR LLC	$296.7M	7,747,648
Nextech Invest, Ltd.	$155.3M	4,055,861
JANUS HENDERSON GROUP PLC	$148.9M	3,890,589
Alta Partners Management Company, L.P.	$146.4M	3,823,425
FARALLON CAPITAL MANAGEMENT LLC	$137.1M	3,580,818
TCG Crossover Management, LLC	$124.4M	3,248,980
Commodore Capital LP	$94.8M	2,475,000
BlackRock, Inc.	$84.9M	2,217,929
Paradigm Biocapital Advisors LP	$78.7M	2,054,991

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TYRA on your watchlist

Track score changes the day Tyra Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TYRA a good stock to buy?

13F Pro's AI-powered analysis of Tyra Biosciences, Inc. (TYRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TYRA are available on the TYRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TYRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TYRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tyra Biosciences, Inc.'s investment landscape.